This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Puma Biotechnology Inc
11/5/2026
Good afternoon. My name is LaTanya, and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the speaker's formal remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press the star key, then the number 1 on your telephone keypad. If you would like to withdraw your question, please press star 2. If you should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference call over to Mariann Ohanesian, Senior Director of IR for PUMA Technology. You may begin the conference.
Thank you, LaTonya. Good afternoon and welcome to PUMA's conference call to discuss our earnings results for the third quarter of 2026. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of PUMA Biotechnology, Maximo Nougues, Chief Financial Officer, Heather Blaber, Senior Vice President of Marketing, and Roger Storms, Senior Vice President of Sales. After the close today, PUMA issued a news release detailing earnings results for the third quarter of 2026. That news release, the slides that Roger will refer to, and a webcast of this call are accessible via the homepage and investor sections of our website at Pumabiotechnology.com. The webcast and presentation slides will be archived on our website and available for replay for the next 90 days. Today's conference call will include statements about PUMA's future expectations, plans and prospects that constitute forward-looking statements for purposes of federal securities laws. Such statements are subject to risks and uncertainties and actual events and results may differ from those expressed in these forward-looking statements. For a full discussion of these risks and uncertainties, please review our periodic and current reports filed with the SEC from time to time, including our annual report on Form 10-K for the year ended December 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this live conference call, November 5, 2026. PUMA undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, we may refer to certain non-GAAP financial measures that involve adjustments to our GAAP figures. We believe these non-GAAP metrics may be useful to investors as a supplement to but not a substitute for our GAAP financial measures. Please refer to our third quarter 2026 earnings release for a reconciliation of our GAAP to non-GAAP results. I will now turn the call over to Alan.
Thank you, Mariann. and thank you all for joining our call today. Today PUMA reported total revenue for the third quarter of 2026 of $55.1 million. Total revenue includes product revenue net which consists entirely of Neuralink sales as well as royalties from our sub-licensees. Product revenue net was $54.1 million in the third quarter of 2026, an increase from $53.6 million reported in Q2 2026 and 51.9 million reported in Q3 2025. As a reminder to investors, PUMA reported Nearlink sales includes both U.S. net sales of Nearlinks and product supply revenues of Nearlinks to PUMA's ex-U.S. partners. Product revenue for the third quarter of 2026 included approximately 1.5 million of inventory drawdown at our specialty pharmacies and specialty distributors. Royalty Revenue was slightly below $1 million in the third quarter of 2026 compared to $2.9 million in Q2 2026 and $2.6 million in Q2 2025. We reported 2,818 bottles of Neuralink sold in the third quarter of 2026 compared to 2,929 bottles sold in Q2 2026. In Q3 2026, we estimate that inventory decreased by 82 bottles. In Q1, 2026, new prescriptions were down approximately 13% compared to Q2, 2026 and total prescriptions were down approximately 5% compared to Q2, 2026. Roger will provide further details in his comments and slides. I will now provide updates from PUMA's ongoing phase two trials of alicerib in small cell lung cancer and HER2 negative ER positive breast cancer, also referred to as ALISCA lung 1, Aliska Lung 2, and Aliska Breast 1. Heather Blaber and Roger Storms will add additional color on New Orleans commercial activities. Maximo Nougues will follow with highlights of the key components of our financial statements for the third quarter of 2026. As investors are aware, PUMA currently has three ongoing phase two studies of our investigational drug, Alicertib. Aliska Breast 1, a phase two trial of Alicertib in combination with endocrine treatment, and patients with HER2-negative hormone receptor-positive recurrent or metastatic breast cancer, ALISCA Lung 1, a Phase II study looking at the efficacy of allosterative monotherapy in patients with small cell lung cancer, and ALISCA Lung 2, a Phase II trial of allosterative in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. As a reminder, the ALISCA Breast 1 trial investigates allosterative in combination with endocrine treatment consisting of either anastrozole, exomesting, letrozole, fulvestrant, or tamoxifen in patients with HER2 negative, hormone receptor positive, recurrent, or metastatic breast cancer. Patients must be chemotherapy naive in the recurrent or metastatic setting, have had previous treatment with a CDK4-6 inhibitor, and have received at least two prior lines of endocrine therapy to be eligible for the trial. Patients were initially dosed with alacertib given at either 30 milligrams 40 mg or 50 mg twice daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle in combination with endocrine therapy of the investigator's choice. Patients must not have previously been treated with the endocrine treatment in the metastatic setting that will be given in combination with L-acertib in the trial. Interim data from this trial was presented on the company's first quarter conference call. As discussed during that presentation, the company believes that the data obtained to date from Mellisca Breast 1 is providing a preliminary indication of potentially better activity in patients with biomarkers where the aurora kinase pathway plays a role. Based on feedback that we have received from breast cancer key opinion leaders on this interim data, the trial has been amended such that we are only continuing enrollment in the 40 milligram and 50 milligram dose groups only. We began enrollment under that amended protocol during Q3. We are anticipating that updated interim data from the ALISCA Breast 1 study, including longer patient follow-up, will be presented at the San Antonio Breast Cancer Symposium in December. Based on our initial analysis of this data, we believe that the data from ALISCA Breast 1 is supportive of a Phase 3 trial of alicerib in patients with HER2-negative hormone receptor-positive Recurrent or Metastatic Breast Cancer. The company is looking to engage with global regulatory authorities regarding the design of this Phase 3 trial in the first half of 2027. With respect to the ALISCO Lung 1 study, as investors are aware, PUMA has an ongoing Phase 2 trial of our investigational drug alicerib to investigate the efficacy of alicerib monotherapy in patients with extensive stage small cell lung cancer. Interim data from this trial was presented on the company's first quarter earnings call. As discussed during that presentation, the company believes that the data obtained to date from a LISCA lung is providing a preliminary indication of potentially better activity in patients with biomarkers where the Aurora kinase pathway plays a role. As was also discussed on the call, the company previously amended the trial to increase the dose from 50 milligrams BID to 60 milligrams BID. Dosing in this trial was further increased to 70 mg BID, and the company is currently enrolling patients at this 70 mg BID dose level. PUMA also initiated a second trial of Alacertib in advanced small cell lung cancer, ALISCA Lung 2, where Alacertib is given in combination with Paclitaxel, similar to the Phase II randomized trial that was previously published in the Journal of Thoracic Oncology in September 2026. The company anticipates that they will have additional interim data from the ALISCA Lung 1 trial and initial data from ALISCA Lung 2 in 2027. As mentioned on prior earnings calls and in response to investor questions, PUMA continues to evaluate several commercial stage and development stage drugs to potentially in-license or acquire that would allow the company to diversify itself and leverage proven existing R&D, regulatory, and commercial infrastructure. The company will keep investors updated on this as it progresses. I will now turn the call over to Heather Blaber for an update on our marketing initiatives. Roger Storms will follow with a review of our commercial performance during the quarter.
You're reading a preview of the PBYI Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing